The US Food and Drug Administration (FDA) has approved Merck & Co’s Keytruda plus chemotherapy as a first-line treatment for non-small cell lung cancer (NSCLC).
AstraZeneca has widened the licence for its cancer drug Tagrisso (osimertinib) in Europe after regulators gave it the green-light for first-line use against additional types of non-small ce
NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).
Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.